Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health

  • Silvia Ciotti USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Mary Micheli USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Antonella Cometa USL Umbria 2, Department of Rehabilitation, S.M. Stella, Orvieto, Italy
  • Claudia De Carlo USL Umbria 2, Department of Rehabilitation, Domus Gratiae, Terni, Italy
  • Giancarlo Martini USL Umbria 2, Department of Rehabilitation, Ospedale di Cascia, Cascia, Italy
  • Andrea Marona Department of Neuroradiology, USL Umbria 2, Ospedale S.G. Battista, Foligno, Italy
  • Laura Filippetti USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Diego Carducci USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista, Foligno, Italy
  • Silvano Baratta USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy
  • Mauro Zampolini USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista, Foligno, Italy
  • Francesco Corea USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista, Foligno, Italy

Keywords

Multiple sclerosis, ICF, neurorehabilitation, delta-9-tetrahydrocannabinol/cannabidiol

Abstract

Multiple sclerosis (MS) is the most common cause of non-traumatic neurological disability in young adults. It has effects at different levels: physical, emotional, psychological, cognitive and social, with a great variety of signs and symptoms. In particular, spasticity contributes to reducing the motor performance of patients with MS, causing pain, reduction in distance walked and limitations in social life. We present the case of a 39-year-old woman with MS. She was treated with delta-9-tetrahydrocannabinol/cannabidiol and the outcome was assessed with the International Classification of Functioning Disability and Health core set framework.

VIEW THE ENTIRE ARTICLE

References

  • Wicks CR, Ward K, Stroud A, Tennant A, Ford HL . Multiple sclerosis and employment: associations of psychological factors and work instability. J Rehabil Med 2016; 48799 –805.
  • WHO. International Classification of Functioning, Disability and Health. Trento: Erickson; 2002.
  • Holper L, Coenen M, Weise A, Stucki G, Cieza A, Kesselring J. Characterization of functioning in multiple sclerosis using the ICF. J Neurol 2010;257(1):103–113.
  • Corea F, Barbi M, Bellanti A, Ciotti S, Micheli S, Brustenghi P, et al. Analysis of activities and participation according to the International Classification of Functioning (ICF) Stroke Core Set on a cohort of ischemic stroke survivors. Cerebrovasc Dis 2014;71(Suppl): 72.
  • Scarponi F, Sattin D, Leonardi M, Raggi A, Zampolini M. The description of severe traumatic brain injury in light of the ICF classification. Disabil Rehabil 2009;31(Suppl 1): S134–S143.
  • Ciotti S, Bianconi F, Saraceni VM, Vulpiani MC, Rinonapoli G, Zampolini M, et al. Narrative medicine in amyotrophic lateral sclerosis and a rehabilitation project based on International Classification of Functioning, Disability and Health. Am J Phys Med Rehabil 2018;97(11):832–838.
  • Coenen M, Cieza A, Freeman J, Khan F, Miller D, Weise A, et al. The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference. J Neurol 2011;258(8):1477–1488.
  • Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, et al. The Italian MultipleSclerosis Register. Neurol Sci 2019;40(4):907.
  • Carotenuto A, Costabile T, De Lucia M, Moccia M, Falco F, Petruzzo M, et al.Predictors of nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. J Neurol 2020;267(6):1737–1743. doi: 10.1007/s00415-020-09739-x.
  • Published: 2021-10-08

    Issue: 2021: Vol 8 No 9 (view)

    Section: Articles

    How to cite:
    1.
    Ciotti S, Micheli M, Cometa A, De Carlo C, Martini G, Marona A, Filippetti L, Carducci D, Baratta S, Zampolini M, Corea F. Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health. EJCRIM 2021;8 doi:10.12890/2021_002298.

    Most read articles by the same author(s)